{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T03:38:51Z","timestamp":1778989131483,"version":"3.51.4"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The development of portal hypertension leads to a majority of complications associated with chronic liver disease. Therefore, adequate treatment of portal hypertension is crucial in the management of such patients. Current treatment options are limited and consist mainly of medications that decrease the hyperdynamic circulation, such as non-selective beta blockers, and treatment of hypervolemia with diuretics. Despite these options, mortality rates have not improved over the last two decades. Newer, more effective treatment options are necessary to help improve survival and quality of life in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Areas covered<\/jats:title><jats:p>Multiple preclinical models and clinical studies have demonstrated potential efficacy of a variety of new treatment modalities. We introduce treatment options including the use of vasodilation promotors, vasoconstriction inhibitors, anticoagulants, antiangiogenics, and anti-inflammatory drugs. We examine the most recent studies for treatment options within these drug classes and offer insights as to which show the most promise in this field.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methodology<\/jats:title><jats:p>Published studies that identified novel medical treatment options of portal hypertension were searched using PubMed (<jats:ext-link>https:\/\/pubmed.ncbi.nlm.nih.gov\/<\/jats:ext-link>). Clinical trials listed in Clinicaltrials.gov were also searched with a focus on more recent and ongoing studies, including those with completed recruitment. Searching with key terms including \u201cportal hypertension\u201d as well as individually searching specific treatment medications that were listed in other publications was carried out. Finally, current societal guidelines and recent review articles relevant to the management of portal hypertension were evaluated, and listed references of interest were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Many ongoing early phase studies demonstrate promising results and may shape the field of portal hypertension management in future. As concrete results become available, larger RCTs will be required before making definitive conclusions regarding safety and efficacy and whether or not they can be incorporated into routine clinical practice. Statins, anticoagulants, and PDE inhibitors have been among the most studied and appear to be most promising.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.974182","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T14:57:31Z","timestamp":1665413851000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Current and investigational drugs in early clinical development for portal hypertension"],"prefix":"10.3389","volume":"9","author":[{"given":"Sasan","family":"Sakiani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/jgh.13200","article-title":"A short history of portal hypertension and of its management.","volume":"31","author":"Balducci","year":"2016","journal-title":"J Gastroenterol Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1172\/JCI100883","article-title":"Splenic vein pressure in congestive splenomegaly (banti\u2019s syndrome).","volume":"16","author":"Thompson","year":"1937","journal-title":"J Clin Invest."},{"key":"B3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/hep.21090","article-title":"Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation.","volume":"43","author":"Blasco","year":"2006","journal-title":"Hepatology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/hep.20062","article-title":"The hepatic venous pressure gradient: anything worth doing should be done right.","volume":"39","author":"Groszmann","year":"2004","journal-title":"Hepatology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1053\/j.gastro.2008.03.007","article-title":"Portal hypertension and its complications.","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/bcp.12980","article-title":"Peripheral vasoconstriction induced by beta-adrenoceptor blockers: a systematic review and a network meta-analysis.","volume":"82","author":"Khouri","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.gtc.2010.08.015","article-title":"Clinical pharmacology of portal hypertension.","volume":"39","author":"Minano","year":"2010","journal-title":"Gastroenterol Clin North Am."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/ajg.2017.175","article-title":"Trends in 30-Day and 1-year mortality among patients hospitalized with cirrhosis from 2004 to 2013.","volume":"112","author":"Kanwal","year":"2017","journal-title":"Am J Gastroenterol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-019-0716-8","article-title":"All about portal vein: a pictorial display to anatomy, variants and physiopathology.","volume":"10","author":"Carneiro","year":"2019","journal-title":"Insights Imaging."},{"key":"B10","author":"Lautt","year":"2009","journal-title":"Hepatic Circulation: Physiology and Pathophysiology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"G792","DOI":"10.1152\/ajpgi.00229.2009","article-title":"Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.","volume":"297","author":"Theodorakis","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cld.2006.08.017","article-title":"Hepatic fibrosis, stellate cells, and portal hypertension.","volume":"10","author":"Rockey","year":"2006","journal-title":"Clin Liver Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.4254\/wjh.v2.i6.208","article-title":"Physiopathology of splanchnic vasodilation in portal hypertension.","volume":"2","author":"Martell","year":"2010","journal-title":"World J Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1053\/j.gastro.2003.12.012","article-title":"Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice.","volume":"126","author":"Fernandez","year":"2004","journal-title":"Gastroenterology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases.","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1055\/s-2008-1059304","article-title":"The effect of alcohol on portal vein hemodynamics in nutritional-toxic liver cirrhosis.","volume":"118","author":"Klein","year":"1993","journal-title":"Dtsch Med Wochenschr."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/hep.28992","article-title":"Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study.","volume":"65","author":"Berzigotti","year":"2017","journal-title":"Hepatology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0140-6736(80)90063-X","article-title":"Propranolol\u2013a medical treatment for portal hypertension?","volume":"2","author":"Lebrec","year":"1980","journal-title":"Lancet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/apt.12634","article-title":"Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis.","volume":"39","author":"Sinagra","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/hep.28264","article-title":"Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension.","volume":"63","author":"Villanueva","year":"2016","journal-title":"Hepatology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jhep.2020.05.011","article-title":"Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites.","volume":"73","author":"Tellez","year":"2020","journal-title":"J Hepatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/apt.15439","article-title":"Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis.","volume":"50","author":"Tergast","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.23775","article-title":"Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites.","volume":"52","author":"Serste","year":"2010","journal-title":"Hepatology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.cgh.2016.01.012","article-title":"Nonselective beta-blockers and survival in patients with cirrhosis and ascites: a systematic review and meta-analysis.","volume":"14","author":"Chirapongsathorn","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"7612","DOI":"10.3748\/wjg.v27.i44.7612","article-title":"Role of early transjugular intrahepatic portosystemic stent-shunt in acute variceal bleeding: an update of the evidence and future directions.","volume":"27","author":"Khan","year":"2021","journal-title":"World J Gastroenterol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1136\/gutjnl-2019-320221","article-title":"Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension.","volume":"69","author":"Tripathi","year":"2020","journal-title":"Gut."},{"key":"B29","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10620-016-4399-4","article-title":"An algorithm for management after transjugular intrahepatic portosystemic shunt placement according to clinical manifestations.","volume":"62","author":"Kim","year":"2017","journal-title":"Dig Dis Sci."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/1756284818811294","article-title":"Advances in therapeutic options for portal hypertension.","volume":"11","author":"Vilaseca","year":"2018","journal-title":"Therap Adv Gastroenterol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jhep.2012.03.007","article-title":"Functional aspects on the pathophysiology of portal hypertension in cirrhosis.","volume":"57","author":"Garcia-Pagan","year":"2012","journal-title":"J Hepatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/hep.1840210505","article-title":"Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension.","volume":"21","author":"Wanless","year":"1995","journal-title":"Hepatology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/j.1538-7836.2008.03015.x","article-title":"Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies.","volume":"6","author":"Anstee","year":"2008","journal-title":"J Thromb Haemost."},{"key":"B34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jvir.2012.02.012","article-title":"Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions.","volume":"23","author":"Patel","year":"2012","journal-title":"J Vasc Interv Radiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/hep.27783","article-title":"Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study.","volume":"62","author":"Cerini","year":"2015","journal-title":"Hepatology."},{"key":"B36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.hepres.2006.07.004","article-title":"Long-term administering low anticoagulant activity heparin can lessen rat hepatic fibrosis induced by either CCl(4) or porcine serum injection.","volume":"36","author":"Li","year":"2006","journal-title":"Hepatol Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jhep.2015.12.003","article-title":"Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats.","volume":"64","author":"Cerini","year":"2016","journal-title":"J Hepatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis.","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/hep.29084","article-title":"The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.","volume":"65","author":"Vilaseca","year":"2017","journal-title":"Hepatology."},{"key":"B40","author":"David Garcia","year":"2019","journal-title":"Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"G407","DOI":"10.1152\/ajpgi.00441.2016","article-title":"Rationale for the use of statins in liver disease.","volume":"312","author":"Schierwagen","year":"2017","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","article-title":"Beneficial cardiovascular pleiotropic effects of statins.","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation."},{"key":"B43","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase.","volume":"46","author":"Trebicka","year":"2007","journal-title":"Hepatology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/gut.2010.220913","article-title":"Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver.","volume":"60","author":"Gracia-Sancho","year":"2011","journal-title":"Gut."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/labinvest.2012.106","article-title":"Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats.","volume":"92","author":"Klein","year":"2012","journal-title":"Lab Invest."},{"key":"B46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jhep.2012.08.026","article-title":"The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins.","volume":"58","author":"Marrone","year":"2013","journal-title":"J Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","article-title":"Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells.","volume":"53","author":"Trebicka","year":"2010","journal-title":"J Hepatol."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-015-0248-8","article-title":"Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.","volume":"15","author":"Chong","year":"2015","journal-title":"BMC Gastroenterol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology."},{"key":"B50","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial.","volume":"47","author":"Pollo-Flores","year":"2015","journal-title":"Dig Liver Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4254\/wjh.v9.i5.270","article-title":"Addition of simvastatin to carvedilol non responders: a new pharmacological therapy for treatment of portal hypertension.","volume":"9","author":"Wani","year":"2017","journal-title":"World J Hepatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.","volume":"30","author":"Bishnu","year":"2018","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B53","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis.","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology."},{"key":"B54","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in veterans with Hepatitis C-related compensated cirrhosis.","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology."},{"key":"B55","year":"2024","journal-title":"Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3748\/wjg.v24.i3.438","article-title":"Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: a case report with 8 years follow-up.","volume":"24","author":"Deibert","year":"2018","journal-title":"World J Gastroenterol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1053\/j.gastro.2003.11.046","article-title":"Nitric oxide in gastrointestinal health and disease.","volume":"126","author":"Shah","year":"2004","journal-title":"Gastroenterology."},{"key":"B58","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1365-2036.2006.02735.x","article-title":"Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver \u2013 results of a pilot study.","volume":"23","author":"Deibert","year":"2006","journal-title":"Aliment Pharmacol Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.cgh.2010.01.017","article-title":"Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis.","volume":"8","author":"Tandon","year":"2010","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.dld.2014.10.018","article-title":"The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study.","volume":"47","author":"Kreisel","year":"2015","journal-title":"Dig Liver Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/liv.12559","article-title":"Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure.","volume":"35","author":"Mehta","year":"2015","journal-title":"Liver Int."},{"key":"B62","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/apt.13844","article-title":"Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV\/HCV patients with advanced liver disease.","volume":"45","author":"Schwabl","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/hep.30199","article-title":"Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension.","volume":"69","author":"Garcia-Tsao","year":"2019","journal-title":"Hepatology."},{"key":"B64","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/hep4.1360","article-title":"Emricasan ameliorates portal hypertension and liver fibrosis in cirrhotic rats through a hepatocyte-mediated paracrine mechanism.","volume":"3","author":"Gracia-Sancho","year":"2019","journal-title":"Hepatol Commun."},{"key":"B65","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jhep.2013.07.044","article-title":"Pathological bacterial translocation in liver cirrhosis.","volume":"60","author":"Wiest","year":"2014","journal-title":"J Hepatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.cgh.2012.02.025","article-title":"Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites.","volume":"10","author":"Kalambokis","year":"2012","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/j.1365-2036.2009.03958.x","article-title":"Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis.","volume":"29","author":"Vlachogiannakos","year":"2009","journal-title":"Aliment Pharmacol Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/jgh.12070","article-title":"Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.","volume":"28","author":"Vlachogiannakos","year":"2013","journal-title":"J Gastroenterol Hepatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/hep.28898","article-title":"Rifaximin has no effect on hemodynamics in decompensated cirrhosis: a randomized, double-blind, placebo-controlled trial.","volume":"65","author":"Kimer","year":"2017","journal-title":"Hepatology."},{"key":"B70","doi-asserted-by":"publisher","first-page":"702","DOI":"10.5009\/gnl16478","article-title":"Rifaximin and propranolol combination therapy is more effective than propranolol monotherapy for the reduction of portal pressure: an open randomized controlled pilot study.","volume":"11","author":"Lim","year":"2017","journal-title":"Gut Liver."},{"key":"B71","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1478-3231.2009.02010.x","article-title":"Lack of effect of norfloxacin on hyperdynamic circulation in bile duct-ligated rats despite reduction of endothelial nitric oxide synthase function: result of unchanged vascular Rho-kinase?","volume":"29","author":"Hennenberg","year":"2009","journal-title":"Liver Int."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1111\/liv.12539","article-title":"Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites.","volume":"34","author":"Rincon","year":"2014","journal-title":"Liver Int."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1111\/liv.12280","article-title":"VSL#3 (R) probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis.","volume":"33","author":"Jayakumar","year":"2013","journal-title":"Liver Int."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/liv.12172","article-title":"Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial.","volume":"33","author":"Gupta","year":"2013","journal-title":"Liver Int."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hep.31578","article-title":"Single session fecal microbiota transplantation in decompensated cirrhosis: an initial experience of clinical endpoints.","volume":"72","author":"Dhiman","year":"2020","journal-title":"Hepatology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/hep.27117","article-title":"Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis.","volume":"60","author":"Granzow","year":"2014","journal-title":"Hepatology."},{"key":"B77","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/gutjnl-2015-309600","article-title":"Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.","volume":"66","author":"Klein","year":"2017","journal-title":"Gut."},{"key":"B78","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1476-5381.2009.00158.x","article-title":"Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.","volume":"157","author":"Hennenberg","year":"2009","journal-title":"Br J Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/hep.22758","article-title":"Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.","volume":"49","author":"Mejias","year":"2009","journal-title":"Hepatology."},{"key":"B80","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1365-2036.2011.04896.x","article-title":"The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma\u2013a pilot study.","volume":"35","author":"Pinter","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016978","article-title":"Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.","volume":"6","author":"Coriat","year":"2011","journal-title":"PLoS One."},{"key":"B82","doi-asserted-by":"publisher","first-page":"36220","DOI":"10.18632\/oncotarget.26333","article-title":"The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension.","volume":"9","author":"Uschner","year":"2018","journal-title":"Oncotarget."},{"key":"B83","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1159\/000445268","article-title":"Farnesoid X receptor agonists and other bile acid signaling strategies for treatment of liver disease.","volume":"34","author":"Halilbasic","year":"2016","journal-title":"Dig Dis."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28836","article-title":"Liver capsule: FXR agonists against liver disease.","volume":"64","author":"Fuchs","year":"2016","journal-title":"Hepatology."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/cells10081846","article-title":"Farnesoid X receptor as target for therapies to treat cholestasis-induced liver injury.","volume":"10","author":"Petrescu","year":"2021","journal-title":"Cells."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14138-6","article-title":"Sumoylation inhibitors synergize with FXR agonists in combating liver fibrosis.","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat Commun."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology."},{"key":"B88","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.","volume":"66","author":"Schwabl","year":"2017","journal-title":"J Hepatol."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9010060","article-title":"The non-steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH model.","volume":"9","author":"Schwabl","year":"2021","journal-title":"Biomedicines."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00126-9","article-title":"FDA rejects NASH drug.","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat Rev Drug Discov."},{"key":"B91","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/17512433.2021.1894127","article-title":"Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis.","volume":"14","author":"Al Attar","year":"2021","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension.","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology."},{"key":"B93","year":"2023","journal-title":"Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/srep44612","article-title":"Effect of modulation of PPAR-gamma activity on Kupffer cells M1\/M2 polarization in the development of non-alcoholic fatty liver disease.","volume":"7","author":"Luo","year":"2017","journal-title":"Sci Rep."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH.","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med."},{"key":"B96","year":"2024","journal-title":"A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)\/Fibrosis 3 (F3) Stage of Liver Fibrosis."},{"key":"B97","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1478-3231.2008.01664.x","article-title":"Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension.","volume":"28","author":"Biecker","year":"2008","journal-title":"Liver Int."},{"key":"B98","year":"2017","journal-title":"Serelaxin to Lower Portal Pressure."},{"key":"B99","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1527-3466.2004.tb00136.x","article-title":"Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status.","volume":"22","author":"Fiorucci","year":"2004","journal-title":"Cardiovasc Drug Rev."},{"key":"B100","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/liv.14757","article-title":"Effect of ET-A blockade on portal pressure and hepatic arterial perfusion in patients with cirrhosis: a proof of concept study.","volume":"41","author":"Zipprich","year":"2021","journal-title":"Liver Int."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1517\/14656566.6.8.1337","article-title":"Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence.","volume":"6","author":"Provencher","year":"2005","journal-title":"Expert Opin Pharmacother."},{"key":"B102","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S2213-2600(19)30091-8","article-title":"Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.","volume":"7","author":"Sitbon","year":"2019","journal-title":"Lancet Respir Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/hep.510300235","article-title":"Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension.","volume":"30","author":"Kamath","year":"1999","journal-title":"Hepatology."},{"key":"B104","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11684-019-0689-5","article-title":"Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl4-induced cirrhotic rats.","volume":"13","author":"Zhang","year":"2019","journal-title":"Front Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2177\/jsci.27.40","article-title":"Beneficial effect of glucocorticosteroids for esophageal varices due to idiopathic portal hypertension following systemic lupus erythematosus.","volume":"27","author":"Yamamoto","year":"2004","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi."},{"key":"B106","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000088545","article-title":"Platelet aggregation in portal hypertension and its modification by ultra-low doses of aspirin.","volume":"34","author":"Eizayaga","year":"2005","journal-title":"Pathophysiol Haemost Thromb."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069309","article-title":"Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis.","volume":"8","author":"Gao","year":"2013","journal-title":"PLoS One."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/hep.23596","article-title":"Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis.","volume":"51","author":"Steib","year":"2010","journal-title":"Hepatology."},{"key":"B109","year":"2017","journal-title":"Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1007\/s00535-003-1222-8","article-title":"Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity.","volume":"38","author":"Baik","year":"2003","journal-title":"J Gastroenterol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/j.1572-0241.2003.07497.x","article-title":"Portal pressure response to losartan compared with propranolol in patients with cirrhosis.","volume":"98","author":"De","year":"2003","journal-title":"Am J Gastroenterol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"587","DOI":"10.21608\/jesp.2016.88263","article-title":"Portal hypertension treatment with candesartan plus propranolol for nine months restores normal portal circulation hemodynamic pattern.","volume":"46","author":"Abd Alla","year":"2016","journal-title":"J Egypt Soc Parasitol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1023\/A:1013790610327","article-title":"Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension.","volume":"47","author":"Debernardi-Venon","year":"2002","journal-title":"Dig Dis Sci."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034230","article-title":"Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO\/PKG pathway in the bile-duct-ligated rat.","volume":"7","author":"Luo","year":"2012","journal-title":"PLoS One."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.974182\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T14:57:37Z","timestamp":1665413857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.974182\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":114,"alternative-id":["10.3389\/fmed.2022.974182"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.974182","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"article-number":"974182"}}